| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Philip J Cowe. A "fact of the matter" may not exist in scientific narratives such as serotonin and depression. BMJ (Clinical research ed.). vol 350. 2015-07-27. PMID:25976091. |
a "fact of the matter" may not exist in scientific narratives such as serotonin and depression. |
2015-07-27 |
2023-08-13 |
Not clear |
| Qi-Xiang Song, Christopher J Chermansky, Lori A Birder, Longkun Li, Margot S Damase. Brain-derived neurotrophic factor in urinary continence and incontinence. Nature reviews. Urology. vol 11. issue 10. 2015-07-15. PMID:25224451. |
serotonin and noradrenaline reuptake inhibitors, used to treat both depression and sui, result in enhanced bdnf levels. |
2015-07-15 |
2023-08-13 |
Not clear |
| Chris F Johnson, Nadine J Dougall, Brian Williams, Stephen A MacGillivray, Alasdair I Buchanan, Richard D Hasset. Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study. BMC family practice. vol 15. 2015-07-10. PMID:25540076. |
this study's aim was to investigate patient factors associated with selective serotonin re-uptake inhibitor (ssri) prescribed daily dose for depression treatment in general practice. |
2015-07-10 |
2023-08-13 |
Not clear |
| Hitoshi Takahashi, Keizo Yoshida, Hisashi Higuchi, Mitsuhiro Kamata, Kazuyuki Inoue, Toshio Suzuki, Jun Ishigook. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression. Neuropsychobiology. vol 70. issue 3. 2015-07-07. PMID:25358426. |
the purpose of this study was to investigate whether bcl1 polymorphisms of grs are associated with the antidepressant effect of milnacipran, a serotonin noradrenaline reuptake inhibitor (snri), and fluvoxamine, a selective serotonin reuptake inhibitor (ssri), in japanese patients with depression. |
2015-07-07 |
2023-08-13 |
Not clear |
| Nitasha Agrawal, Sergio Marco-Peiró, Josep Esteve-Romero, Abhilasha Durgbanshi, Devasish Bose, Juan Peris-Vicente, Samuel Carda-Broc. Determination of paroxetine in blood and urine using micellar liquid chromatography with electrochemical detection. Journal of chromatographic science. vol 52. issue 10. 2015-07-02. PMID:24448669. |
paroxetine is a potent selective serotonin reuptake inhibitor used for the treatment of depression and related mood disorders. |
2015-07-02 |
2023-08-12 |
human |
| David Heal. Serotonin and depression. BMJ (Clinical research ed.). vol 350. 2015-06-30. PMID:25900074. |
serotonin and depression. |
2015-06-30 |
2023-08-13 |
Not clear |
| Richard C Shelto. What are the comparative benefits and harms of augmentation treatments in major depression? The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-30. PMID:25919851. |
augmentation strategies, particularly the use of atypical antipsychotics to augment selective serotonin reuptake inhibitors (ssris), have proliferated over the last 15 years, and 2 atypical antipsychotics, aripiprazole and quetiapine, have received us food and drug administration approval for adjunctive therapy in treatment-resistant depression. |
2015-06-30 |
2023-08-13 |
Not clear |
| Peter A Shapiro, Richard P Sloan, Chetram Deochand, Ana M Franceschi, Christine Delorenzo, J John Mann, Ramin V Parse. Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment. Synapse (New York, N.Y.). vol 68. issue 11. 2015-06-26. PMID:25043294. |
although depression in major depressive disorder is associated with low serotonin transporter binding, animal models suggest that ifn-associated mood effects are linked to increased presynaptic serotonin transporter binding. |
2015-06-26 |
2023-08-13 |
human |
| Peter A Shapiro, Richard P Sloan, Chetram Deochand, Ana M Franceschi, Christine Delorenzo, J John Mann, Ramin V Parse. Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment. Synapse (New York, N.Y.). vol 68. issue 11. 2015-06-26. PMID:25043294. |
this study tested the hypotheses that ifn administration to human subjects increases presynaptic serotonin binding activity, and that this effect correlates with incident depression symptoms. |
2015-06-26 |
2023-08-13 |
human |
| Elena Dale, Benny Bang-Andersen, Connie Sánche. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical pharmacology. vol 95. issue 2. 2015-06-25. PMID:25813654. |
hence efforts to increase monoamine transmission by inhibiting serotonin (5-ht) and norepinephrine (ne) transporters has been a central theme in depression research since the 1960s. |
2015-06-25 |
2023-08-13 |
Not clear |
| D J Hellerstein, S A Littl. Current Perspectives on the Diagnosis and Treatment of Double Depression. CNS drugs. vol 5. issue 5. 2015-06-16. PMID:26071047. |
aggressive treatment is recommended for all patients with double depression, but refined treatment strategies based on depressive typology may help to increase compliance, consolidate therapeutic gains and forestall relapse.a growing psychopharmacology literature shows that several different classes of medication [tricyclic antidepressants, monamine oxidase inhibitors, selective serotonin (5-hydroxytryptamine; 5-ht) reuptake inhibitors and others] are effective in the treatment of double depression, although perhaps somewhat less effective than in the treatment of acute major depression. |
2015-06-16 |
2023-08-13 |
Not clear |
| Waldo Oliveira Monteiro Filho, Sandra Maria de Torres, Marleyne José Afonso Accioly Lins Amorim, Anderson Joel Martino Andrade, Rosana Nogueira de Morais, Bruno Mendes Tenorio, Valdemiro Amaro da Silva Junio. Fluoxetine induces changes in the testicle and testosterone in adult male rats exposed via placenta and lactation. Systems biology in reproductive medicine. vol 60. issue 5. 2015-06-12. PMID:24983959. |
fluoxetine is a selective serotonin reuptake inhibitor used to treat depression in pregnant and nursing women. |
2015-06-12 |
2023-08-13 |
rat |
| Micha Milovanovic, Kristoffer Eriksson, Bengt Winblad, Staffan Nilsson, Tomas L Lindahl, Claes Post, Petter Järem. Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clinical biochemistry. vol 47. issue 15. 2015-06-11. PMID:25041722. |
platelets take up and store serotonin (5-ht) that plays an important role in the pathogenesis of severe depression. |
2015-06-11 |
2023-08-13 |
Not clear |
| Xiao-Juan Ma, Jie Zhao, Zhen-Yu Feng, Jian-Min Chang, Shuang Meng, Hu-Ze Liu, Kai-Fang Fa. [Effects of modified Ganmai Dazao decoction on neuroendocrine system in patients with climacteric depression]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. vol 39. issue 23. 2015-06-11. PMID:25911823. |
this study indicates that modified ganmai dazao decoction has obvious therapeutic effects in the treatment of climacteric depression, and showed equivalent efficacy with deanxit, and modified ganmai dazao decoction has better effect on improving the sleep quality in patients than deanxit, the effect of improved clinical symptoms may be through adjusted levels of 5-ht, ne, e2, fsh and lh of climacteric depression. |
2015-06-11 |
2023-08-13 |
Not clear |
| Veronika Kiryanova, Richard H Dyc. Increased aggression, improved spatial memory, and reduced anxiety-like behaviour in adult male mice exposed to fluoxetine early in life. Developmental neuroscience. vol 36. issue 5. 2015-06-10. PMID:25115143. |
fluoxetine (flx; brand names prozac, sarafem, rapiflux), a selective serotonin reuptake inhibitor, is prescribed for the treatment of depression in pregnant women; however, this commonly prescribed medication could affect fetal brain development as flx crosses the placenta. |
2015-06-10 |
2023-08-13 |
mouse |
| N P Garganeeva, M M Petrova, A A Evsyukov, S Yu Shtarik, D S Kaskaev. [The influence of depression on the course of coronary heart disease and quality of life]. Klinicheskaia meditsina. vol 92. issue 12. 2015-06-10. PMID:25980296. |
these patients treated with selective antidepressants (serotonin reuptake inhibitors) for 6 months experienced a marked decrease in the degree of depression and manifestation of its symptoms, improvedpsycho- social protection and quality of life compared with untreated patients. |
2015-06-10 |
2023-08-13 |
Not clear |
| Andrew A Nierenberg, Roger S McIntyre, Gary S Sach. Improving outcomes in patients with bipolar depression: a comprehensive review. The Journal of clinical psychiatry. vol 76. issue 3. 2015-06-08. PMID:25830453. |
only 3 medications are currently approved in the us for acute bipolar depression: 2 atypical antipsychotics and a combination atypical antipsychotic-selective serotonin reuptake inhibitor. |
2015-06-08 |
2023-08-13 |
Not clear |
| Philip J Cowen, Michael Brownin. What has serotonin to do with depression? World psychiatry : official journal of the World Psychiatric Association (WPA). vol 14. issue 2. 2015-06-05. PMID:26043325. |
what has serotonin to do with depression? |
2015-06-05 |
2023-08-13 |
Not clear |
| Omi Watanab. [Current evaluation of teratogenic and fetotoxic effects of psychotropic drugs]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 116. issue 12. 2015-06-04. PMID:25823351. |
this review focuses on the use of selective serotonin reuptake inhibitors (ssris) during pregnancy, the antidepressants most commonly used to treat depression. |
2015-06-04 |
2023-08-13 |
Not clear |
| Hai-Yin Jiang, Min Deng, Yong-Hua Zhang, Hua-Zhong Chen, Qian Chen, Bing Rua. Specific serotonin reuptake inhibitors prevent interferon-α-induced depression in patients with hepatitis C: a meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. vol 12. issue 9. 2015-05-27. PMID:23648373. |
specific serotonin reuptake inhibitors prevent interferon-α-induced depression in patients with hepatitis c: a meta-analysis. |
2015-05-27 |
2023-08-12 |
Not clear |